financetom
Business
financetom
/
Business
/
Nkarta Posts Narrower Q4 Loss; Discloses Restructuring Plan
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nkarta Posts Narrower Q4 Loss; Discloses Restructuring Plan
Mar 26, 2025 2:40 PM

05:24 PM EDT, 03/26/2025 (MT Newswires) -- Nkarta ( NKTX ) late Wednesday reported a Q4 loss of $0.35 per diluted share, compared with a $0.57 loss a year earlier.

Four analysts polled by FactSet expected a $0.43 loss.

As expected, the company reported no revenue for the quarter ended Dec. 31.

Nkarta ( NKTX ) also disclosed plans for a company-wide reorganization, including a "significant" workforce reduction and cutting its executive ranks by more than 50%. The restructuring is expected to result in $5.5 million to $6.5 million in cash expense.

As of Dec. 31, the company said it had $380.5 million in cash, cash equivalents, restricted cash and investments in marketable securities, which is expected to fund operations into 2029.

Nkarta ( NKTX ) shares were up 5.8% in after-hours activity.

Price: 1.45, Change: +0.08, Percent Change: +5.84

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports
Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports
Oct 26, 2025
Oct 26 (Reuters) - Swiss drugmaker Novartis AG is close to acquiring U.S. biotech Avidity Biosciences ( RNA ) for over $70 per share, Bloomberg News reported on Sunday, citing a person familiar with the matter. Reuters could not immediately confirm the report. ...
Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports
Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports
Oct 26, 2025
(Reuters) -Swiss drugmaker Novartis AG is close to acquiring U.S. biotech Avidity Biosciences ( RNA ) for over $70 per share, Bloomberg News reported on Sunday, citing a person familiar with the matter. Reuters could not immediately confirm the report. ...
Putin's investment envoy Dmitriev continues talks with US officials
Putin's investment envoy Dmitriev continues talks with US officials
Oct 26, 2025
MOSCOW (Reuters) -Russian President Vladimir Putin's special envoy for investment and economic cooperation, Kirill Dmitriev, said on Sunday that he had continued talks with representatives of President Donald Trump's administration in the United States. Dmitriev told Reuters on Oct. 24 that he was in the United States for a long-planned meeting. We have been negotiating with representatives of the U.S....
Bessent says China to delay rare earths rules by a year, buy U.S. soybeans
Bessent says China to delay rare earths rules by a year, buy U.S. soybeans
Oct 26, 2025
WASHINGTON (Reuters) -U.S. Treasury Secretary Scott Bessent said on Sunday that he anticipates that China will revive substantial purchases of U.S. soybeans for several years and will delay its expanded licensing regime for rare earths by a year and re-examine it after two days of trade talks in Malaysia. Bessent told the CBS program Face the Nation that the soybean...
Copyright 2023-2026 - www.financetom.com All Rights Reserved